Selective Inhibition of PI3K Isoforms in Brain Tumors Suppresses Tumor Growth by Increasing Radiosensitivity
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Glioblastoma (GBM) is a malignant brain tumor with poor prognosis. Radioresistance is a major challenge in the treat ment of brain tumors. The development of several types of tumors, including GBM, involves the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway. Upon activation, this pathway induces radioresistance. In this study, we investigated whether additional use of selective inhibitors of PI3K isoforms would enhance radiosensitivity in GBM. Materials and Methods: We evaluated whether radiation combined with PI3K isoform selective inhibitors can suppress radiore sistance in GBM. Glioma 261 expressing luciferase (GL261-luc) and LN229 were used to confirm the effect of combination of radi ation and PI3K isoform inhibitors in vitro. Cell viability was confirmed by clonogenic assay, and inhibition of PI3K/AKT signaling activation was observed by Western blot. To confirm radiosensitivity, the expression of phospho-γ-H2AX was observed by immu nofluorescence. In addition, to identify the effect of a combination of radiation and PI3K-α isoform inhibitor in vivo, an intracranial mouse model was established by implanting GL261-luc. Tumor growth was observed by IVIS imaging, and survival was analyzed using Kaplan–Meier survival curves. Results: Suppression of the PI3K/AKT signaling pathway increased radiosensitivity, and PI3K-α inhibition had similar effects on PI3K-pan inhibition in vitro. The combination of radiotherapy and PI3K-α isoform inhibitor suppressed tumor growth and ex tended survival in vivo. Conclusion: This study verified that PI3K-α isoform inhibition improves radiosensitivity, resulting in tumor growth suppression and extended survival in GBM mice.
Abstract
Purpose: Glioblastoma (GBM) is a malignant brain tumor with poor prognosis. Radioresistance is a major challenge in the treat ment of brain tumors. The development of several types of tumors, including GBM, involves the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway. Upon activation, this pathway induces radioresistance. In this study, we investigated whether additional use of selective inhibitors of PI3K isoforms would enhance radiosensitivity in GBM. Materials and Methods: We evaluated whether radiation combined with PI3K isoform selective inhibitors can suppress radiore sistance in GBM. Glioma 261 expressing luciferase (GL261-luc) and LN229 were used to confirm the effect of combination of radi ation and PI3K isoform inhibitors in vitro. Cell viability was confirmed by clonogenic assay, and inhibition of PI3K/AKT signaling activation was observed by Western blot. To confirm radiosensitivity, the expression of phospho-γ-H2AX was observed by immu nofluorescence. In addition, to identify the effect of a combination of radiation and PI3K-α isoform inhibitor in vivo, an intracranial mouse model was established by implanting GL261-luc. Tumor growth was observed by IVIS imaging, and survival was analyzed using Kaplan–Meier survival curves. Results: Suppression of the PI3K/AKT signaling pathway increased radiosensitivity, and PI3K-α inhibition had similar effects on PI3K-pan inhibition in vitro. The combination of radiotherapy and PI3K-α isoform inhibitor suppressed tumor growth and ex tended survival in vivo. Conclusion: This study verified that PI3K-α isoform inhibition improves radiosensitivity, resulting in tumor growth suppression and extended survival in GBM mice.
참고문헌 (40)
- Gurney JG, "Brain and other central nervous system tumors : rates, trends, and epidemiology", Curr Opin Oncol, 13, pp.160~166 (2001)
- Davis ME, "Glioblastoma : overview of disease and treatment", Clin J Oncol Nurs, 20(5 Suppl), pp.S2~S8 (2016)
- Zhao HF, "Recent advances in the use of PI3K inhibitors for glioblastoma multiforme : current preclinical and clinical development", Mol Cancer, 16, pp.100~ (2017)
- Buckner JC, "Factors influencing survival in high-grade gliomas", Semin Oncol, 30(6 Suppl 19), pp.10~14 (2003)
- Chinot OL, "Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma", N Engl J Med, 370, pp.709~722 (2014)
- Westphal M, "A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma", Eur J Cancer, 51, pp.522~532 (2015)
- Stupp R, "Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter(CENTRIC EORTC 26071-22072 study) : a multicentre, randomised, open-label, phase 3 trial", Lancet Oncol, 15, pp.1100~1108 (2014)
- Kuwahara Y, "Clinically relevant radioresistant cell line : a simple model to understand cancer radioresistance", Med Mol Morphol, 50, pp.195~204 (2017)
- Mukherjee B, "EGFRvIII and DNA double-strand break repair : a molecular mechanism for radioresistance in glioblastoma", Cancer Res, 69, pp.4252~4259 (2009)
- Jamal M, "The brain microenvironment preferentially enhances the radioresistance of CD133(+)glioblastoma stem-like cells", Neoplasia, 14, pp.150~158 (2012)
- Bao S, "Glioma stem cells promote radioresistance by preferential activation of the DNA damage response", Nature, 444, pp.756~760 (2006)
- Li HF, "Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells", Radiat Oncol, 4, pp.43~ (2009)
- Chen Y, "PI3K : a potential therapeutic target for cancer", J Cell Physiol, 227, pp.2818~2821 (2012)
- Guerreiro AS, "Targeting the PI3K p110α isoform inhibits medulloblastoma proliferation, chemoresistance, and migration", Clin Cancer Res, 14, pp.6761~6769 (2008)
- Jia S, "Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis", Nature, 454, pp.776~779 (2008)
- Vanhaesebroeck B, "Molecules in medicine mini-review: isoforms of PI3K in biology and disease", J Mol Med(Berl), 94, pp.5~11 (2016)
- Chuang FC, "PI3k inhibitors(BKM120 and BYL719)as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy", PLoS One, 16, pp.e0245715~ (2021)
- Narayan RS, "Targeting the Akt-pathway to improve radiosensitivity in glioblastoma", Curr Pharm Des, 19, pp.951~957 (2013)
- Nunnery SE, "Management of toxicity to isoform α-specific PI3K inhibitors", Ann Oncol, 30(Suppl 10), pp.x21~x26 (2019)
- Chia S, "Novel agents and associated toxicities of inhibitors of the PI3K", Akt, Curr Oncol, pp.2015, 22[DOI]
- Zhang Y, "Molecular basis for class side effects associated with PI3K", AKT, Expert Opin Drug Metab Toxicol, pp.2019, 15[DOI]
- Massacesi C, "PI3K inhibitors as new cancer therapeutics : implications for clinical trial design", Onco Targets Ther, 9, pp.203~210 (2016)
- Seol MY, "Combining radiation with PI3K isoform-selective inhibitor administration increases radiosensitivity and suppresses tumor growth in non-small cell lung cancer", J Radiat Res, 63, pp.591~601 (2022)
- Chadwick KH, "Molecular theory of cell survival", Instituut voor Toepassing van Atoomenergie in de Landbouw, ~ (1973)
- Ali MY, "Radioresistance in glioblastoma and the development of radiosensitizers", Cancers(Basel), 12, pp.2511~ (2020)
- Vignard J, "Ionizing-radiation induced DNA double-strand breaks : a direct and indirect lighting up", Radiother Oncol, 108, pp.362~369 (2013)
- Aparicio T, "DNA double-strand break repair pathway choice and cancer", DNA Repair(Amst), 19, pp.169~175 (2014)
- Ersahin T, "The PI3K", AKT, Mol Biosyst, pp.2015, 11[DOI]
- Fruman DA, "PI3K and cancer : lessons, challenges and opportunities", Nat Rev Drug Discov, 13, pp.140~156 (2014)
- Prevo R, "Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity", Cancer Res, 68, pp.5915~5923 (2008)
- Bellacosa A, "Activation of AKT kinases in cancer : implications for therapeutic targeting", Adv Cancer Res, 94, pp.29~86 (2005)
- Belda-Iniesta C, "Epidermal growth factor receptor and glioblastoma multiforme : molecular basis for a new approach", Clin Transl Oncol, 10, pp.73~77 (2008)
- Kao GD, "Inhibition of phosphatidylinositol-3-OH kinase", Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation, 2007, pp.282, 21206~21212
- Rodon J, "Development of PI3K inhibitors : lessons learned from early clinical trials", Nat Rev Clin Oncol, 10, pp.143~153 (2013)
- Wymann MP, "Phosphoinositide 3-kinase signalling--which way to target?", Trends Pharmacol Sci, 24, pp.366~376 (2003)
- Vanhaesebroeck B, "Signalling by PI3K isoforms : insights from gene-targeted mice", Trends Biochem Sci, 30, pp.194~204 (2005)
- Mizrachi A, "Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma", Nat Commun, 8, pp.14292~ (2017)
- Elkabets M, "mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer", Sci Transl Med, 5, pp.196ra99~ (2013)
- Wen PY, "First-in-human phase I study to evaluate the brain-penetrant PI3K", mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma, 2020, pp.26, 1820~1828
- Diao W, "Behaviors of glioblastoma cells in in vitro microenvironments", Sci Rep, 9, pp.85~ (2019)